Genomed

Genomed Dividend

The Dividend of Genomed (GEN.WA) as of Nov 20, 2026 is 1.00 PLN.

Dividend

1.00PLN

Dividend yield

2.86 %

Last updated:

How much dividend does Genomed 2026 pay?

According to the latest status from November 2026, Genomed paid a total of 1.00 PLN per share in dividends within the last 12 months. With the current Genomed price of 35.00 PLN, this corresponds to a dividend yield of - %. A dividend is paid times per year.

At today's price the dividend yield works out to roughly 2.86%. The payout ratio is around 132% of earnings.

Historical Genomed Dividends

Historical Genomed Dividends
PaydateDividend
1.00PLN

The Genomed Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2018
0.00 PLN
Jan 1, 2019
1.00 PLN
Jan 1, 2020
0.00 PLN
Jan 1, 2021
0.00 PLN
Jan 1, 2022
0.00 PLN
Jan 1, 2023
0.00 PLN
Jan 1, 2024
0.00 PLN
Jan 1, 2025
0.00 PLN
The Genomed Dividend history
YEARDividendYoY
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN-100.00%
1.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—

Is the Genomed Dividend Safe?

Genomed has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Genomed dividend payout ratio

In 2025, Genomed had a payout ratio of 131.89%. The payout ratio indicates the percentage of the company's profits that Genomed distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
131.89 %
Jan 1, 2019
131.89 %
Jan 1, 2020
131.89 %
Jan 1, 2021
131.89 %
Jan 1, 2022
131.89 %
Jan 1, 2023
131.89 %
Jan 1, 2024
131.89 %
Jan 1, 2025
131.89 %

Dividend Details

Understanding Genomed's Dividend Distributions

Genomed’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Genomed's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Genomed's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Genomed’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomed stock

The current dividend yield of Genomed is 2.86 %.

Genomed paid dividends every year for the past 0 years.

Genomed is assigned to the 'Health' sector.

To receive the latest dividend of Genomed from 8/16/2019 amounting to 1 PLN, you needed to have the stock in your portfolio before the ex-date on 7/2/2019.

The last dividend was paid out on 8/16/2019.

In the year 2019, Genomed distributed 1 PLN as dividends.

The dividends of Genomed are distributed in PLN.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Genomed